GarudaTx is a biotechnology company focused on developing innovative therapies for rare diseases. The company leverages its proprietary gene therapy platform to create treatments that address unmet medical needs.

David Scadden

Sean Morrison

GarudaTx

Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.

Eterna Therapeutics Inc.

Garuda Therapeutics seeks to create a world which eliminates the dependency on donor or patient cells for blood stem cell transplants. Our platform technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible transgene-free blood stem cell therapies. Like bone marrow transplants, our technology could provide potentially curative therapies for more than 120 diseases. https://garudatx.com

Mass General Brigham Ventures

Monashee Investment Management

Aisling Capital

Ridgeback Capital

Sectoral Asset Management

Northpond Ventures

OrbiMed

Resilience

Cormorant Asset Management

Alexandria Venture Investments

Garuda Therapeutics

March 1 is #EmployeeAppreciationDay! Made up of science-driven individuals with a passion for serving patients, the #GarudaTx team is making our mission to build the future of blood #stemcell therapies a reality. 
 
Today and every day, we are incredibly grateful for the Garuda team and their dedication to delivering transformative medicines to patients.

Garuda is proud to recognize February 29 as #RareDiseaseDay – a day dedicated to raising awareness and inspiring action for the 300 million people living with a #RareDisease worldwide. 
 
At Garuda, we’re developing off-the-shelf, durable blood stem cell therapies with the potential to provide curative treatment options to millions of patients with rare diseases. 
 
Learn more about our approach: bit.ly/3NrS9t0

What does 2024 hold for #biopharma?
 
Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah expects an increased appetite for off-the-shelf blood stem cell therapies due to their ability to bypass many challenges associated with current treatment options.
 
Check it out: bit.ly/49BZlfA

Congratulations to Rob Labriola, Executive Director of Regulatory Operations at Garuda, who has been selected to serve on the Drug Information Association (DIA) conference planning committee for DIA’s Regulatory Submissions, Information, and Document Management (RSIDM) Forum, taking place February 12-14, 2024 in North Bethesda, MD.
 
Rob will also lead the Forum track on Building and Sustaining Successful RSIDM Foundations. Register for this can’t miss event which will feature over 90 diverse speakers from regulatory, industry and academia: bit.ly/48PqknX

Garuda Therapeutics’ Co-founder, President & CEO Dhvanit Shah will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10 at 9:30 am PT.
 
We look forward to connecting in San Francisco.

Metric
Company Name	GarudaTx	Eterna Therapeutics Inc.
Symbol		ERNA
MSH ID	COM:GARUDATX	COM:ETERNATX
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Biotechnology	Biotechnology
Country	US	US
Stage
Employee Count	66	8
Website	garudatx.com	brooklynitx.com
LinkedIn	garuda-therapeutics
Founders

Metric
Market Cap		9.90M
Enterprise Value
Monthly Web Traffic		270.57K
Web Traffic Growth		0.55
Valuation
Raised Capital

Metric
Revenue		68K
Revenue (LTM)
Revenue (NTM)
Gross Profit		-1.29M
EBITDA		-19.55M
Operating Income		-20.67M
Net Income		-21.67M
EPS		-4.08
Diluted EPS		-4.08
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		-5.88
Operating Profit Margin		-135.73
EBITDA Margin		-287.51
Net Profit Margin		-147.65
Return on Equity		15.58
Return on Assets		-0.44
Return on Capital Employed		-0.50

COM:GARUDATX

GarudaTx

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		-0.42
P/B Ratio		2.34
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		192.73
EV Multiple		2.09

Metric
Days Sales Outstanding		12.71K
Days Payables Outstanding		4.45K
Days Inventory Outstanding
Operating Cycle		2.28K
Cash Conversion Cycle		1.79K
Asset Turnover		0.00

Metric
Operating Cash Flow		-20.41M
Free Cash Flow		-20.43M
Cash Flow to Debt		-0.38
Operating Cash Flow/Sales		-101.81
Free Cash Flow Yield		-2.54

Metric
Cash & Equivalents		7.58M
Accounts Receivable		527K
Inventory
Goodwill		2.04M
Debt to Capitalization		2.84
Debt to Assets		0.79
Current Ratio		0.73
Quick Ratio		1.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		28.90
R&D to Revenue		130.82
SG&A to Revenue		252.08